VACH Voyager Acquisition Corp./Cayman Islands

CIK 0002006815 10 ready 8-Ks latest May 29, 2026, 4:01 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 10

Latest filing May 29, 2026, 4:01 PM ET

Top materiality 0.85

Event mix m_and_a ×7 · other_material ×3

Sentiment 1 pos · 1 neg · 8 neu

Recent 8-K filings for VACH

Highest-materiality recent filing

Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed

March 18, 2026, 7:59 PM ET M&A materiality 0.85 negative item 5.07 item 7.01 item 8.01 item 9.01

Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.
25,217,315 Class A shares redeemed (~99.67%), leaving ~$885,556 in trust account.

Read filing →

May 29, 2026, 4:01 PM ET other material materiality 0.80 neutral item 1.01 item 2.03 item 3.02 item 7.01 item 9.01 ◈ Debt Financings

Voyager/Veraxa secure $27.5M senior secured notes and $50M share purchase agreement

$27.5M senior secured notes due Aug 2027, monthly amortization of $2.75M, with warrants to buy 2.39M shares at $11.50.
March 18, 2026, 7:59 PM ET M&A materiality 0.85 negative item 5.07 item 7.01 item 8.01 item 9.01

Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed

Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.
February 27, 2026, 6:59 PM ET M&A materiality 0.65 neutral item 7.01 item 9.01

VERAXA shareholders approve merger with Voyager SPAC; CHF 223,400 capital increase

Shareholders approved absorption merger of VERAXA into Veraxa Biotech Holding AG; combined entity to rename to Veraxa Biotech AG.
February 3, 2026, 6:59 PM ET M&A materiality 0.65 neutral item 1.01 item 9.01 ◈ Material Agreements ×2

Voyager Acquisition raises Veraxa merger consideration to $1.35B; sponsor to forfeit shares

Aggregate merger consideration increased by $50M to $1,350,000,000.
October 21, 2025, 7:59 PM ET M&A materiality 0.50 positive item 1.01 item 9.01

Voyager Acquisition extends Veraxa Biotech deal deadline to Aug 7, 2026; removes SPAC termination fee

Amendment to Business Combination Agreement extends drop-dead date to August 7, 2026.
September 5, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 7.01 item 9.01

SPAC Voyager to combine with Veraxa Biotech at ~$1.5B enterprise value; close expected Q4 2025

Pro forma combined enterprise value of ~$1.5B; Veraxa shareholders roll over 100% of equity.
July 16, 2025, 7:59 PM ET M&A materiality 0.40 neutral item 1.01 item 9.01

Voyager Acquisition Corp. adds PubCo and Merger Sub as parties to existing business combination agreement

PubCo (Veraxa Biotech Holding AG) and Merger Sub joined the April 22, 2025 BCA with Voyager and Veraxa Biotech AG, dated July 16, 2025.
April 23, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 1.01 item 7.01 item 9.01

Voyager Acquisition Corp. to merge with Veraxa Biotech AG; expected Q4 2025 close

SPAC will merge with Merger Sub, then Veraxa will merge into PubCo, a Swiss public company.
August 16, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Voyager Acquisition Corp. closes $253M IPO and $7.7M private placement

Closed IPO of 25,300,000 units at $10.00 each, generating $253.0M in gross proceeds.
August 14, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 3.02 item 8.01 item 9.01

Voyager Acquisition Corp. closes $253M IPO, including full over-allotment; units start trading on Nasdaq

25,300,000 units sold at $10/unit for gross proceeds of $253M; includes 3.3M over-allotment units.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event m_and_a

1 positive 1 negative 8 neutral

source · VACH on sec.gov